TIDMABC
RNS Number : 5777G
ABCAM Plc
02 July 2012
For immediate release 2 July 2012
ABCAM PLC
("Abcam" or "the Company")
PDMR dealing
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of the following PDMR:
Name Matching Shares Date of transfer Total subsequent Percentage
now transferred to beneficial beneficial of share
to beneficial ownership holding capital
ownership
----------------- ----------------- ----------------- ----------------- -----------
Philippe Cotrel 90 30 June 2012 7,028 0.004%
----------------- ----------------- ----------------- ----------------- -----------
For further information please contact:
Abcam + 44 (0) 1223 696 000
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Adviser
& Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker + 44 (0) 20 7418 8900
Andy Crossley - Corporate Broking
Buchanan + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie
Cowles
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 590 staff across its eight operating companies.
Abcam now has an online catalogue of over 92,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBRGDLSBDBGDC
